HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Lowers Price Target to $12
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $24 to $12.
HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $24 to $12.